摘要
同种异体肝脏移植的急性排斥反应是肝脏移植排斥中最常见的一种。急性排斥反应常发生在移植肝功能恢复后，尤其在术后5～15天最多见，经免疫抑制剂逆转后，仍然可以在术后半年以至一年内多次重复间隔出现。而移植肝超急性排斥反应发生非常迅速，基本上在移植后数分钟后发生，甚至在松开肝动脉血管钳时就同步开始。超急性排斥反应是异种肝移植的重要障碍，该反应对机体和移植肝的损害极大。
出处
《器官移植内科学杂志》
2009年第3期161-163,共3页
Journal of Transplant Medicine
同被引文献14
-
1Scott LJ, McKeage K, Kearn SJ, et al . Tacrolirnus , a further update of its use in the management of organ transplantation. Drugs,2003;63(12):1247-1297.
-
2Macphee lAM, Fredericks S, Tai T, et al . Tacrolimus pharmacogenetics polyrnorphisms associated with expression of cytochrome P4S03AS and P-glycoprotein correlate with dose requirement. Transplantation,2002;74(l1): 1486-1489.
-
3Kuypers DIL. Immunosuppressive drug monitoring-what to use in clinical practice today to improve renal graft outcome. Transpl Lnt,200S;23(18): 140-1S0.
-
4Davidson S. Research suggests importance of haplotypes over SNPs. Nat Biotechnol , 2000; 18(11) : 1134-113S.
-
5Li D, Zhang GL, Lou YQ, et al. Genetic polymorphisms in MDR1 and CYP3AS and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther , 2007;32(1):89-9S.
-
6Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolirnus , a comparison across ethnic groups. Clin Pharmacol Ther , 2001; 69(1) :24-3l.
-
7Zhang X, Liu ZH, Zheng J M, et al. Influence of CYP3A5 and MDR1 polyrnorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant,200S; 19(5): 638-643.
-
8Masuda S, Goto M, Okuda M, etal. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. Transplant Proc,200S;37(4):1728-1729.
-
9Wang WL, Jin J, Zheng SS, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3AS gene polymorphisms in Chinese liver transplant patients. Liver Transplant, 2006; 12(S): 775-780.
-
10Wang J, Zeevi A, McCurry K, et al. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 * 3/ * 3 nonexpressors. Transplant Immunol,2006;lS(3) :235-240.
二级引证文献3
-
1卢蕾,杨欣.酶放大免疫检测技术在监测他克莫司血药浓度中的应用[J].中国免疫学杂志,2014,30(9):1294-1296. 被引量：4
-
2周峻臣,李丹滢,方芸,郭宏骞.服用他克莫司的肾移植患者ABCB1基因多态性与术后感染的相关性[J].中国医院药学杂志,2016,36(4):305-309. 被引量：7
-
3罗文辉,秦寅鹏,邵佳,陈凡,高伟,张弋.MDR1基因多态性影响儿童肝移植术后早期他克莫司代谢[J].中华器官移植杂志,2020,41(7):407-411. 被引量：3
-
1刘峰,孙君泓,等.大鼠同种异体肝脏移植凋亡相关蛋白及黏附分子的研究[J].胃肠病学,2002,7(B11):54-54.
-
2苏方士,何翠媚,黄宝红.同种异体肝脏移植的术后护理[J].现代护理,2001,7(4):13-13. 被引量：5
-
3刘玉兰,刘峰,孙君泓.黏附分子在大鼠同种异体肝脏移植免疫反应中的作用[J].中华肝胆外科杂志,2004,10(5):316-319. 被引量：2
-
4穆燕.肝脏移植术中病人保暖的意义及措施[J].临床护理杂志,2005,4(1):39-40. 被引量：19
-
5康玉明,蒙广星,李昭宇.肝移植受体的选择[J].宁夏医学杂志,2007,29(1):92-94.
-
6张红永.同种异体肝脏移植手术后早期胸腹腔出血的处理[J].医学理论与实践,2013,26(18):2436-2437.
-
7张巍,温浩.肿瘤坏死因子-α基因-308多态性与同种异体肝脏移植急性排斥反应的Meta分析[J].循证医学,2006,6(3):154-157.
-
8朱志军,沈中阳.肝脏移植的适应证[J].中华肝脏病杂志,2004,12(6):371-371. 被引量：8
-
9宋世兵,袁炯,修典荣,朱建平,王德臣,蒋斌,傅卫,张同琳.同种异体肝脏移植手术后早期胸腹腔出血的处理[J].中国现代普通外科进展,2002,5(4):234-236. 被引量：2
-
10陈小伍,李利红,朱达坚,戎祯祥,剧永乐.不同途径大鼠骨髓基质干细胞同种异体肝脏移植效果的比较[J].南方医科大学学报,2010,30(9):2151-2153. 被引量：2
